Development of human-like scFv-Fc antibodies neutralizing Botulinum toxin serotype B

References

• Lacy DB, Stevens RC. Sequence homology and structural analysis of the clostridial neurotoxins. J Mol Biol 1999; 291:1091-104; PMID:10518945; http://dx.doi.org/10.1006/jmbi.1999.2945
   PubMed Web of Science ®Google Scholar
• Smith TJ, Lou J, Geren IN, Forsyth CM, Tsai R, Laporte SL, Tepp WH, Bradshaw M, Johnson EA, Smith LA, et al. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralisation. Infect Immun 2005; 73:5450-7; PMID:16113261; http://dx.doi.org/10.1128/IAI.73.9.5450-5457.2005
   PubMed Web of Science ®Google Scholar
• Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001; 285: 1059-70; PMID:11209178; http://dx.doi.org/10.1001/jama.285.8.1059
   PubMed Web of Science ®Google Scholar
• Gelzleichter TR, Myers MA, Menton RG, Niemuth NA, Matthews MC, Langford MJ. Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model. J Appl Toxicol 1999; 19 Suppl 1:S35-8; PMID:10594898; http://dx.doi.org/10.1002/(SICI)1099-1263(199912)19:1+%3cS35::AID-JAT612%3e3.0.CO;2-9
   PubMedGoogle Scholar
• Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev 1982; 46:86-94; PMID:6806598
   PubMedGoogle Scholar
• Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988; 3:333-5; PMID:3211180; http://dx.doi.org/10.1002/mds.870030409
   PubMed Web of Science ®Google Scholar
• Taysse L, Daulon S, Calvet J, Delamanche S, Hilaire D, Bellier B, Breton P. Induction of acute lung injury after intranasal administration of toxin botulinum a complex. Toxicol Pathol 2005; 33:336-42; PMID:15814363; http://dx.doi.org/10.1080/01926230590922884
   PubMed Web of Science ®Google Scholar
• Wein LM, Liu Y. Analyzing a bioterror attack on the food supply: the case of botulinum toxin in milk. Proc Natl Acad Sci U S A 2005; 102:9984-9; PMID:15985558; http://dx.doi.org/10.1073/pnas.0408526102
   PubMed Web of Science ®Google Scholar
• Schantz EJ, Johnson EA. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 1992; 56:80-99; PMID:1579114
   PubMedGoogle Scholar
• Hill KK, Smith TJ, Helma CH, Ticknor LO, Foley BT, Svensson RT, Brown JL, Johnson EA, Smith LA, Okinaka RT, et al. Genetic diversity among botulinum neurotoxin-producing clostridial strains. J Bacteriol 2007; 189:818-32; PMID:17114256; http://dx.doi.org/10.1128/JB.01180-06
   PubMed Web of Science ®Google Scholar
• Kalb SR, Baudys J, Rees JC, Smith TJ, Smith LA, Helma CH, Hill K, Kull S, Kirchner S, Dorner MB, et al. De novo subtype and strain identification of botulinum neurotoxin type B through toxin proteomics. Anal Bioanal Chem 2012; 403:215-26; PMID:22395449; http://dx.doi.org/10.1007/s00216-012-5767-3
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hill KK, Foley BT, Detter JC, Munk AC, Bruce DC, Doggett NA, Smith LA, Marks JD, Xie G, et al. Analysis of the neurotoxin complex genes in clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS One 2007; 2:e1271; PMID:18060065; http://dx.doi.org/10.1371/journal.pone.0001271
   PubMed Web of Science ®Google Scholar
• Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol 1986; 103:535-44; PMID:3015983; http://dx.doi.org/10.1083/jcb.103.2.535
   PubMed Web of Science ®Google Scholar
• Rossetto O, Montecucco, C. Presynaptic neurotoxins with enzymatic activities. Handb Exp Pharmacol 2008; 184:129-70; PMID:18064414; http://dx.doi.org/10.1007/978-3-540-74805-2_6
   PubMedGoogle Scholar
• Schiavo G, Benfenati F, Poulain B, Rossetto O, Polverino de Laureto P, DasGupta BR, Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992; 359:832-5; PMID:1331807; http://dx.doi.org/10.1038/359832a0
   PubMed Web of Science ®Google Scholar
• Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000; 80:717-66; PMID:10747206
   PubMed Web of Science ®Google Scholar
• Mahant N, Clouston PD, Lorentz IT. The current use of botulinum toxin. J Clin Neurosci 2000; 7:389-94; PMID:10942658; http://dx.doi.org/10.1054/jocn.2000.0684
   PubMed Web of Science ®Google Scholar
• Dressler D, Paus S, Seitzinger A, Gebhardt B, Kupsch A. Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia. J Neurol Neurosurg Psychiatry 2013; 84:1014-9; PMID:23687362; http://dx.doi.org/10.1136/jnnp-2012-303608
   PubMed Web of Science ®Google Scholar
• Lim ECH, Seet RCS. Use of botulinum toxin in the neurology clinic. Nat Rev Neurol 2010; 6:624-36; PMID:21045798; http://dx.doi.org/10.1038/nrneurol.2010.149
   PubMed Web of Science ®Google Scholar
• Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, Pavlin JA, Christopher GW, Eitzen EM Jr. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997; 278:399-411; PMID:9244332; http://dx.doi.org/10.1001/jama.1997.03550050061035
   PubMed Web of Science ®Google Scholar
• Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006; 354:462-71; PMID:16452558; http://dx.doi.org/10.1056/NEJMoa051926
   PubMed Web of Science ®Google Scholar
• Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med 1980; 69:567-70; PMID:7191633; http://dx.doi.org/10.1016/0002-9343(80)90469-6
   PubMed Web of Science ®Google Scholar
• Kalb SR, Santana WI, Geren IN, Garcia-Rodriguez C, Lou J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins /B1, /B2, /B3, /B4, and /B5 by a panel of monoclonal anti-BoNT/B antibodies. BMC Biochem 2011; 12:58; PMID:22085466; http://dx.doi.org/10.1186/1471-2091-12-58
   PubMed Web of Science ®Google Scholar
• Adekar SP, Jones RM, Elias MD, Al-Saleem FH, Root MJ, Simpson LL, Dessain SK. Hybridoma populations enriched for affinity-matured human IgGs yield high-affinity antibodies specific for botulinum neurotoxins. J Immunol Methods 2008; 333:156-66; PMID:18313069; http://dx.doi.org/10.1016/j.jim.2008.01.015
   PubMed Web of Science ®Google Scholar
• Amersdorfer P, Wong C, Smith T, Chen S, Deshpande S, Sheridan R, Marks JD. Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries. Vaccine 2002; 20:1640-8; PMID:11858873; http://dx.doi.org/10.1016/S0264-410X(01)00482-0
   PubMed Web of Science ®Google Scholar
• Rasetti-Escargueil C, Liu Y, Rigsby P, Jones RGA, Sesardic D. Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies. Toxicon 2011; 57:1008-16; PMID:21513727; http://dx.doi.org/10.1016/j.toxicon.2011.04.003
   PubMed Web of Science ®Google Scholar
• Jones RG, Alsop TA, Hull R, Tierney R, Rigsby P, Holley J, Sesardic D. Botulinum type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays. Toxicon 2006; 48:246-54; PMID:16870221; http://dx.doi.org/10.1016/j.toxicon.2006.05.007
   PubMed Web of Science ®Google Scholar
• Zhou H, Zhou B, Pellett S, Johnson EA, Janda KD. Selection and characterization of a human monoclonal neutralizing antibody for clostridium botulinum neurotoxin serotype B. Bioorg Med Chem Lett 2009; 19:662-4; PMID:19112017; http://dx.doi.org/10.1016/j.bmcl.2008.12.055
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez C, Geren IN, Lou J, Conrad F, Forsyth C. Wen W, Chakraborti S, Zao H, Manzanarez G, Smith TJ, et al. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin, Protein Eng Des Sel 2011; 24:321-31; PMID:21149386; http://dx.doi.org/10.1093/protein/gzq111
   PubMed Web of Science ®Google Scholar
• Thullier P, Chahboun S, Pelat T. A comparison of human and macaque (macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering. MAbs 2010; 2:528-38; PMID:20562531; http://dx.doi.org/10.4161/mabs.2.5.12545
   PubMed Web of Science ®Google Scholar
• Chahboun S, Hust M, Liu Y, Pelat T, Miethe S, Helmsing S, Jones RGA, Sesardic D, Thullier P. Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnol 2011; 11:113; PMID:22111995; http://dx.doi.org/10.1186/1472-6750-11-113
   PubMed Web of Science ®Google Scholar
• Rasetti-Escargueil C, Jones RGA, Liu Y, Sesardic D. Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice. Toxicon 2009; 53:503-11; PMID:19673096; http://dx.doi.org/10.1016/j.toxicon.2009.01.019
   PubMed Web of Science ®Google Scholar
• Rasetti-Escargueil C, Machado CB, Preneta-Blanc R, Fleck RA, Sesardic D. Enhanced sensitivity to botulinum type A neurotoxin of human neuroblastoma SH-SY5Y cells after differentiation into mature neuronal cells. Botulinum J 2011; 2:30-48; http://dx.doi.org/10.1504/TBJ.2011.041814
   Google Scholar
• Atassi MZ, Dolimbek BZ. Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J 2004; 23:39-52; PMID:15115181; http://dx.doi.org/10.1023/B:JOPC.0000016257.91979.06
   PubMed Web of Science ®Google Scholar
• Tavallaie M, Chenal A, Gillet D, Pereira Y, Manich M, Gibert M, Raffestin S, Popoff MR, Marvaud JC. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS letters 2004; 572:299-306; PMID:15304366; http://dx.doi.org/10.1016/j.febslet.2004.06.094
   PubMed Web of Science ®Google Scholar
• Adekar SP, Takahashi T, Jones RM, Al-Saleem FH, Ancharski DA, Root MJ, Kapadnis BP, Simpson LL, Dessain SK. Neutralization of Botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. PLoS ONE 2008; 3:e3023; PMID:18714390; http://dx.doi.org/10.1371/journal.pone.0003023
   PubMed Web of Science ®Google Scholar
• Avril A, Froude J, Mathieu J, Pelat T, Thullier P. Isolation of antibodies from non-human primates for clinical use. Curr Drug Discov Technol 2014; 11:20-7.
   PubMedGoogle Scholar
• Thullier P, Huish O, Pelat T, Martin ACR. The humanness of macaque antibody sequences. J Mol Biol 2010; 396:1439-50; PMID:20043919; http://dx.doi.org/10.1016/j.jmb.2009.12.041
   PubMed Web of Science ®Google Scholar
• Pelat T, Hust M, Hale M, Lefranc M-P, Dübel S, Thullier P. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol 2009; 9:60; PMID:19563687; http://dx.doi.org/10.1186/1472-6750-9-60
   PubMed Web of Science ®Google Scholar
• Laffly E, Danjou L, Condemine F, Vidal D, Drouet E, Lefranc M-P, Bottex C, Thullier P. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother 2005; 49:3414-20; PMID:16048955; http://dx.doi.org/10.1128/AAC.49.8.3414-3420.2005
   PubMed Web of Science ®Google Scholar
• Rülker T, Voß L, Thullier P, O' Brien LM, Pelat T, Perkins SD, Langermann C, Schirrmann T, Dübel S, Marschall H-J et al. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PloS ONE 2012; 7:e37242; PMID:22666347; http://dx.doi.org/10.1371/journal.pone.0037242
   PubMed Web of Science ®Google Scholar
• Garcia-Rodriguez C, Levy R, Arndt JW, Forsyth CM, Razai A, Lou J, Geren I, Stevens RC, Marks JD. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol 2007; 25:107-16; PMID:17173035; http://dx.doi.org/10.1038/nbt1269
   PubMed Web of Science ®Google Scholar
• Kalb SR, Lou J, Garcia-Rodriguez C, Geren IN Smith TJ, Moura H, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies. PloS ONE 2009; 4:e5355; PMID:19399171; http://dx.doi.org/10.1371/journal.pone.0005355
   PubMed Web of Science ®Google Scholar
• Kalb SR, Garcia-Rodriguez C, Lou J, Baudys J, Smith TJ, Marks JD, Smith LA, Pirkle JL, Barr JR. Extraction of BoNT/A, /B, /E, and /F with a single, high affinity monoclonal antibody for detection of botulinum neurotoxin by Endopep-MS. PLoS ONE 2010; 5:e12237; PMID:20808925; http://dx.doi.org/10.1371/journal.pone.0012237
   PubMed Web of Science ®Google Scholar
• Razai A, Garcia-Rodriguez C, Lou J, Geren IN, Forsyth CM, Robles Y, Tsai R, Smith TJ, Smith LA, Siegel RW, Feldhaus M, Marks JD. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol 2005;351:158-69; PMID:16002090; http://dx.doi.org/10.1016/j.jmb.2005.06.003
   PubMed Web of Science ®Google Scholar
• Nowakowski A1, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 2002; 99:11346-50; PMID:12177434; http://dx.doi.org/10.1073/pnas.172229899
   PubMed Web of Science ®Google Scholar
• Sepulveda J, Mukherjee J, Tzipori S, Simpson LL, Shoemaker CB. Efficient serum clearance of Botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect Immun 2010; 78:756-763; PMID:19917718; http://dx.doi.org/10.1128/IAI.01084-09
   PubMed Web of Science ®Google Scholar
• Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, Bedenice D. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS ONE 2012; 7:e29941; PMID:22238680; http://dx.doi.org/10.1371/journal.pone.0029941
   PubMed Web of Science ®Google Scholar
• Diamant E, Lachmi B-E, Keren A, Barnea A, Marcuk H, Cohen S. Evaluating the synergistic neutralizing effect of anti-botulinum oligoclonal antibody preparations. PLoS ONE 2014; 9:87089; http://dx.doi.org/10.1371/journal.pone.0087089
   PubMed Web of Science ®Google Scholar
• Miethe S, Rasetti-Escargueil C, Liu Y, Chahboun S, Pelat T, Avril A, Frenzel A, Schirrmann T, Thullier P, Sesardic D. and Hust M. Development of neutralizing scFV-Fc against botulinum neurotoxin A light chain from a macaque immune library. mAbs 2014; 6:446-459; PMID:24492304; http://dx.doi.org/10.4161/mabs.27773
   PubMed Web of Science ®Google Scholar
• Abhinandan KR, Martin AC. Analyzing the “degree of humanness” of antibody sequences. J Mol Biol 2007; 369:852-62; PMID:17442342; http://dx.doi.org/10.1016/j.jmb.2007.02.100
   PubMed Web of Science ®Google Scholar
• Pelat T, Hust M, Thullier P. Obtention and engineering of non-human primate (NHP) antibodies for therapeutics. Mini Rev Med Chem 2009; 9:1633-8; PMID:20105119; http://dx.doi.org/10.2174/138955709791012283
   PubMed Web of Science ®Google Scholar
• Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc M-P, Thullier P. Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 2008; 384:1400-7; PMID:18976662; http://dx.doi.org/10.1016/j.jmb.2008.10.033
   PubMed Web of Science ®Google Scholar
• Mazuet C, Dano J, Popoff MR, Creminon C, Volland H. Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity. PLoS ONE 2010; 5:e12416; PMID:20865035; http://dx.doi.org/10.1371/journal.pone.0012416
   PubMed Web of Science ®Google Scholar
• Shone CC, Tranter HS. Growth of Clostridia and preparation of their neurotoxins. In Montecucco C (Ed.), Clostridial neurotoxins. Berlin: Springer-Verlag, 1995:143-160
   Google Scholar
• Ferracci G, Marconi S, Mazuet C, Jover E, Blanchard MP, Seagar M, Popoff M, Lévêque C. A label-free biosensor assay for botulinum neurotoxin B in food and human serum. Anal Biochem 2011; 410:281-288; PMID:21134347; http://dx.doi.org/10.1016/j.ab.2010.11.045
   PubMed Web of Science ®Google Scholar
• Hust M, Dübel S. Phage display vectors for the in vitro generation of human antibody fragments. Methods Mol Biol 2005; (Clifton, N.J.), 295, 71-96. http://www.ncbi.nlm.nih.gov/pubmed/15596889; PMID:15596889
   PubMedGoogle Scholar
• Schütte M, Thullier P, Pelat T, Wezler X, Rosenstock P, Hinz D, Kirsch MI, Hasenberg M, Frank R, Schirrmann T, Gunzer M, Hust M, Dübel S. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PloS ONE 2009; 4:e6625; PMID:19675673; http://dx.doi.org/10.1371/journal.pone.0006625
   PubMed Web of Science ®Google Scholar
• Frenzel A1, Kügler J, Wilke S, Schirrmann T, Hust. Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol Biol 2014;1060:215-43; PMID:24037844; http://dx.doi.org/10.1007/978-1-62703-586-6_12
   PubMedGoogle Scholar
• Pelat T, Hust M, Laffly E, Condemine F, Bottex C, Vidal D, Lefranc P, Dübel S, Thullier P. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 2007; 51:2758-64; PMID:17517846; http://dx.doi.org/10.1128/AAC.01528-06
   PubMed Web of Science ®Google Scholar
• Jäger V, Büssow K, Wagner A, Weber S, Hust M, Frenzel A, Schirrmann T. High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol 2013;13:52; http://dx.doi.org/10.1186/1472-6750-13-52
   PubMed Web of Science ®Google Scholar
• Schuck P, Minton AP. Analysis of mass transport-limited binding kinetics in evenescent wave biosensors. Anal Biochem 1996; 240:262-272; PMID:8811920; http://dx.doi.org/10.1006/abio.1996.0356
   PubMed Web of Science ®Google Scholar
• Alamyar E, Duroux P, Lefranc MP, Giudicelli V. IMGT(®) tools for the nucleotide analysis of immunoglobulin (IG) and T cell receptor (TR) V-(D)-J repertoires, polymorphisms, and IG mutations: IMGT/V-QUEST and IMGT/HighV-QUEST for NGS. Methods Mol Biol 2012; 882:569-604; PMID:22665256; http://dx.doi.org/10.1007/978-1-61779-842-9_32
   PubMedGoogle Scholar
• Ehrenmann F, Lefranc MP. IMGT/DomainGapAlign: the IMGT® tool for the analysis of IG, TR, MH, IgSF, and MhSF domain amino acid polymorphism. Methods Mol Biol 2012; 882:605-33; PMID:22665257; http://dx.doi.org/10.1007/978-1-61779-842-9_33
   PubMedGoogle Scholar
• Lefranc MP, Ehrenmann F, Ginestoux C, Giudicelli V, Duroux P. Use of IMGT(®) databases and tools for antibody engineering and humanization. Methods Mol Biol 2012; 907:3-37; PMID:22907343; http://dx.doi.org/10.1007/978-1-61779-974-7_1
   PubMedGoogle Scholar
• Jones RGA, Ochiai M, Liu Y, Ekong T, Sesardic D. Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. J Immunol Methods 2008; 329:92-101; PMID:17976638; http://dx.doi.org/10.1016/j.jim.2007.09.014
   PubMed Web of Science ®Google Scholar
• Sesardic D, McLellen K, Ekong TA, Das RG. Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. Pharmacol Toxicol 1996; 78:283-8; PMID:8737961; http://dx.doi.org/10.1111/j.1600-0773.1996.tb01376.x
   PubMedGoogle Scholar
• Sesardic D, Jones RGA, Leung T, Alsop T, Tierney R. Detection of antibodies against botulinum toxins. Mov Disord 2004; 19:85-91; http://dx.doi.org/10.1002/mds.20021
   Web of Science ®Google Scholar